CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.310
+0.070 (3.12%)
At close: Oct 23, 2026, 4:00 PM EDT
2.240
-0.070 (-3.03%)
After-hours: Oct 23, 2026, 7:42 PM EDT
CervoMed Revenue
CervoMed had revenue of $331.30K in the twelve months ending June 30, 2026, down -95.74% year-over-year. In the year 2025, CervoMed had annual revenue of $4.01M, down -58.86%. That makes CervoMed the 44,997th largest company in the world by revenue and 6,469th in the United States.
Revenue (ttm)
$331.30K
Revenue Growth
-95.74%
P/S Ratio
105.42
Revenue / Employee
$22,086
Employees
15
Market Cap
34.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.01M | -5.73M | -58.86% |
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 71.67K | -302.88K | -80.87% |
| Dec 31, 2012 | 374.54K | -195.93K | -34.35% |
| Dec 31, 2011 | 570.48K | 530.29K | 1,319.48% |
| Dec 31, 2010 | 40.19K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 40.19K | -268.57K | -86.98% |
| Dec 31, 2007 | 308.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 18.67M |
| Veru Inc. | 16.89M |
| Evaxion | 7.49M |
| EyePoint | 2.79M |
| eXoZymes | -700.00 |
CRVO News
- 12 days ago - CervoMed presents initial data from neflamapimod trial - TheFly
- 26 days ago - CervoMed neflamapimod update removes key overhang, says Jones - TheFly
- 26 days ago - CervoMed announces PK results with new neflamapimod oral tablet formula - TheFly
- 26 days ago - CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit - GlobeNewsWire
- 4 weeks ago - CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 5 weeks ago - CervoMed Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - CervoMed Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 6 weeks ago - CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 - GlobeNewsWire